Statin treatment for children and adolescents with heterozygous familial hypercholesterolaemia: A systematic review and meta-analysis

Atherosclerosis

Volumn 195, Issue 2, 2007, Pages 339-347

  Arambepola, C ^a   Farmer, A J ^a   Perera, R ^a   Neil, H A W ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

Children; Familial hypercholesterolaemia; HMG CoA reductase inhibitors; Statins; Systematic review

Indexed keywords

ATORVASTATIN; COLESTIPOL; MEVINOLIN; PLACEBO; PRAVASTATIN; SIMVASTATIN;

ABDOMINAL PAIN; ARTICLE; CELL FUNCTION; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CREATININE BLOOD LEVEL; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FAMILIAL HYPERCHOLESTEROLEMIA; FLU LIKE SYNDROME; FOLLOW UP; HEADACHE; HUMAN; INFECTION; META ANALYSIS; MYALGIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ADOLESCENT; CHILD; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 36148976818     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2006.09.030     Document Type: Article

References (60)

1. Goldstein J.L., Hobbs H.H., and Brown M.S. Familial hypercholesterolaemia. In: Scriver C.R., Beaudet A.L., Sly W.S., and Valle D. (Eds). Metabolic and molecular bases of inherited disease. 8th ed. (1995), McGraw-Hill, New York 1981-2030
2. Scientific Steering Committee on behalf of Simon Broome Register Group. The risk of fatal coronary heart disease in familial hypercholesterolaemia. Br Med J 303 (1991) 893-896
3. Scientific Steering Committee on behalf of Simon Broome Familial Hyperlipidaemia Register Group. Mortality in treated heterozygous familial hypercholesterolaemia: implications for patient management. Atherosclerosis 142 (1999) 105-112
4. Kaste M., and Koivisto P. Risk of brain infarction in familial hypercholesterolaemia. Stroke 19 (1988) 1097-1100
5. Sorenson K.E., Celermajer D.S., Georgakopoulos D., Hatcher G., Betteridge D.J., and Deanfield J.E. Impairment of endothelial-dependent dilatation is an early event in children with familial hypercholesterolaemia and is related to lipoprotein (a) level. J Clin Invest 93 (1994) 50-55
6. Wiegman A., de Groot E., Hutten B.A., et al. Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia. Lancet 363 (2004) 369-370
7. Stone N.J., Levy R.I., Fredrickson D.S., et al. Coronary artery disease in 116 kindred with familial type II hyperlipoproteinaemia. Circulation 49 (1974) 476-488
8. Slack J. Risks of ischaemic heart disease in familial hyperlipidaemic states. Lancet ii (1969) 1380-1382
9. British Cardiac Society, British Hypertension Society, Diabetes UK, HEART UK, Primary Care Cardiovascular Society, Stroke Association: JBS2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005;91(Suppl 5):1-52.
10. Neil H.A.W., Hawkins M.M., Durrinton P.N., Betteridge D.J., Capps N.E., and Humphries S.E. for the Simon Broome Familial Hyperlipidaemia Register and Scientific Steering Committee. Non-coronary heart disease mortality and risk of fatal cancer in patients with treated heterozygous familial hypercholesterolaemia. Atherosclerosis 179 (2005) 293-297
11. Kane J.P., Malloy M.J., Ports T.A., Phillips N.R., Diehl J.C., and Havel R.J. Regression of coronary atherosclerosis during treatment of familial hypercholesterolaemia with combined drug regimens. JAMA 264 (1990) 3007-3012
12. Thompson G.R., Maher V.M., Matthews S., et al. Familial Hypercholesterolaemia Regression Study: a randomised trial of low-density-lipoprotein apheresis. Lancet 345 (1995) 811-816
13. Brown G., Albers J.J., Fisher L.D., et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 323 (1990) 1289-1298
14. Smilde T.J., van Wissen S., Wollersheim H., Trip M.D., Kastelein J.P., and Stalenhoef A.F.H. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective randomized, double-blind trial. Lancet 357 (2001) 577-581
15. Baigent C., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278
16. Civeira F., and For international panel on management of familial hypercholesterolaemia. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolaemia. Atherosclerosis 173 (2004) 55-68
17. Wray R., Neil H.A.W., and Rees J.A.E. Screening for hyperlipidaemia in childhood: recommendations of the British Hyperlipidaemia Association. J R Coll Phys (Lond) 30 (1996) 115-118
18. National Cholesterol Education Program. Report of the expert panel on blood cholesterol levels in children and adolescents. Pediatrics 89 (1992) 525-584
19. Jadad A.R., Moore R.A., Caroll D., Jenkinson C., Reynolds D.J., Gavaghan D.J., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary. Control Clin Trials 17 (1996) 1-12
20. Follmann D., Elliott P., Suh I., and Cutler J. Variance imputation for overviews of clinical trials with continuous response. J Clin Epidemiol 45 (1992) 769-773
21. Wiegman A., Hutten B.A., de Groot E., Rodenburg J., Bakker H.D., Büller H.R., et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia. A randomized controlled trial. JAMA 292 (2004) 331-337
22. Rodenburg J., Vissers M.N., Wiegman A., Miller E.R., Ridker P.M., Witztum J.L., et al. Oxidized low-density lipoprotein in children with familial hypercholesterolemia and unaffected siblings. J Am Coll Cardiol 47 (2006) 1803-1810
23. Koeijvoets K.C.M.C., Rodenburg J., Hutten B.A., Wiegman A., Kastelein J.J.P., and Sijbrands E.J.G. Low-density lipoprotein receptor genotype and response to pravastatin in children with familial hypercholesterolemia: substudy of an intima-media thickness trial. Circulation 112 (2005) 3168-3173
24. de Jongh S., Ose L., Szamosi T., Gagné C., Lambert M., Scott R., et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia. A randomized, double-blind, placebo-controlled trial with simvastatin. Circulation 106 (2002) 2231-2237
25. Stein E.A., Illingworth D.R., Kwiterovich P.O., Liacouras C.A., Siimes M.A., Jacobson M.S., et al. Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia. A randomized controlled trial. JAMA 281 (1999) 137-144
26. de Jongh S., Lilien M.R., Roodt J., Stroes E.S.G., Bakker H.D., and Kastelein J.J.P. Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J Am Coll Cardiol 40 (2002) 2117-2121
27. McCrindle B.W., Ose L., and Marais A.D. Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial. J Pediatr 142 (2003) 74-80
28. Clauss S.B., Holmes K.W., Hopkins P., Stein E., Cho M., Tate A., et al. Efficacy and safety of lovastatin therapy in adolescent girls with heterozygous familial hypercholesterolemia. Pediatrics 116 (2005) 682-688
29. Knipscheer H.C., Boelen C.C., Kastelein J.J., et al. Short-term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia. Pediatr Res 39 (1996) 867-871
30. Couture P., Brun L.D., Szots F., et al. Association of specific LDL receptor gene mutations with differential plasma lipoprotein response to simvastatin in young French Canadians with heterozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 18 (1998) 1007-1012
31. Vohl M., Szots F., Lelièvre M., et al. Influence of LDL receptor gene mutation and apo E polymorphism on lipoprotein response to simvastatin treatment among adolescents with heterozygous familial hypercholesterolemia. Atherosclerosis 160 (2002) 361-368
32. McCrindle B.W., Helden E., Cullen-Dean G., and Conner W.T. A randomized crossover trial of combination pharmacologic therapy in children with familial hyperlipidemia. Pediatr Res 51 (2002) 715-721
33. Stefanutti C., Lucani G., Vivenzio A., and Di Giacomo S. Diet only and diet plus simvastatin in the treatment of heterozygous familial hypercholesterolemia in childhood. Drugs Exp Clin Res 25 (1999) 23-28
34. Lambert M., Lupien P.J., Gagne C., et al. Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin. Canadian Lovastatin in Children Study Group. Pediatrics 97 (1996) 619-628
35. Athyros V.G., Papageorgiou A.A., and Kontopoulos A.G. Long-term treatment with atorvastatin in adolescent males with heterozygous familial hypercholesterolemia. Atherosclerosis 163 (2002) 205-206
36. Ducobu J., Brasseur D., Chaudron J.M., Deslypere J.P., Muls E., and Thomson M. Simvastatin use in children. Lancet 339 (1992) 1488
37. Hedman M., Matikainen T., Föhr A., et al. Efficacy and safety of pravastatin in children and adolescents with heterozygous familial hypercholesterolemia: a prospective clinical follow-up study. J Clin Endocrinol Metab 90 (2005) 1942-1952
38. Hedman M., Miettinen T.A., Gylling H., Ketomäki A., and Antikainen M. Serum noncholesterol sterols in children with heterozygous familial hypercholesterolemia undergoing pravastatin therapy. J Pediatr 148 (2006) 241-246
39. Dirisamer A. The effect of low-dose simvastatin in children with familial hypercholesterolaemia: a 1-year observation. Eur J Pediatr 162 (2003) 421-425
40. Sinzinger H., Schmid P., Pirich C., et al. Treatment of hypercholesterolaemia in children. Lancet 340 (1992) 548-549
41. Stein E.A. Treatment of familial hypercholesterolemia with drugs in children. Arteriosclerosis 1 Suppl (1989) 145-151
42. Hedman M., Neuvonen P.J., Neuvonen M., Holmberg C., and Antikainen M. Pharmacokinetics and pharmacodynamics of pravastatin in children with familial hypercholesterolemia. Clin Pharmacol Ther 74 (2003) 178-185
43. Kano K., Nishikura K., Yamada Y., and Arisaka O. No effect of fluvastatin on the bone mineral density of children with minimal change glomerulonephritis and some focal mesangial cell proliferation, other than an ameliorating effect on their proteinuria. Clin Nephrol 63 2 (2005) 74-79
44. Kano K., Nishikura K., Yamada Y., and Arisaka O. Effect of fluvastatin and dipyridamole on proteinuria and renal function in childhood IgA nephropathy with mild histological findings and moderate proteinuria. Clin Nephrol 60 2 (2003) 85-89
45. Kasiske B.L., Tortorice K.L., Heim-Duthoy K.L., Goryance J.M., and Rao K.V. Lovastatin treatment of hypercholesterolemia in renal transplant recipients. Transplantation 49 1 (1990) 95-100
46. Han Z.M., Chen X.D., Zhang H., and Yang D.S. The observation of effect of lovastatin on hyperlipidemia of children with nephritic syndrome. Clin Med Chin 17 8 (2001) 632-633
47. Law M.R., Wald N.J., and Rudnicka A.R. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. Br Med J 326 (2003) 1423-1429
48. Moher D., Cook D.J., Eastwood S., Olkin I., Rennie D., and Stroup D.F. Improving the quality of reports of meta-analyses of randomised controlled trials: The QUORUM statement: the QUORUM Group. Lancet 354 (1999) 1896-1900
49. Moher D., Schulz K.F., and Altman D.G. For the CONSORT Group. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 357 (2001) 1191-1194
50. Rodenburg J., Vissers M.N., Wiegman A., Trip M.D., Bakker H.D., and Kastelein J.P. Familial hypercholesterolaemia in children. Curr Opin Lipidol 15 (2004) 405-411
51. Tonstad S. Treatment of children with familial hypercholesterolaemia. Expert Rev Cardiovasc Ther 1 (2003) 135-141
52. Duplaga B.E. Treatment of childhood hypercholesterolaemia with HMG-CoA reductase inhibitors. Ann Pharmacother 33 (1999) 1224-1227
53. Graham D.J., Staffa J.A., Shatin D., et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 292 (2004) 2585-2590
54. Tonstad S., Joakimsen O., Stensland-Bugge E., et al. Risk factors related to carotid intima-media thickness and plaque in children with familial hypercholesterolaemia and control subjects. Arterioscler Thomb Vasc Biol 16 (1996) 984-991
55. Heiberg A., and Slack J. Familial similarities in the age of coronary death in familial hypercholesterolaemia. Br Med J 2 (1977) 493-495
56. Wiegman A., Rogenburg J., et al. Family history and cardiovascular risk in familial hypercholesterolaemia. Circulation 107 (2003) 1473-1478
57. Neil H.A.W., Seagroatt V., Betteridge D.J., et al. Established and emerging coronary risk factors in patients with familial hypercholesteroleamia. Heart 90 (2004) 1431-1437
58. Edison R.J., and Muenke M. Mechanistic and epidemiologic considerations in the evaluation of adverse birth outcomes following gestational exposure to statins. Am J Med Genet 131A (2004) 287-298
59. Gibb H., and Scialli A.R. Statin drugs and congential anomalies. Am J Med Genet 135A (2005) 230-231
60. Umans-Eckenhausen M.A.W., Defesche J.C., Sijbrands E.J.G., Scheerder R.L.J.M., and Kastelein J.J.P. Review of first 5 years of screening for familial hypercholesterolaemia. Lancet 357 (2001) 165-168